Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
- 620 South 20th Street, NHB 104
-
Birmingham, Alabama, United States
- Cooper Green Hospital
-
-
California
-
Lakewood, California, United States
- Southern California Clinical Trials
-
Palmdale, California, United States
- Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Wheat Ridge, Colorado, United States
- Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Norwalk, Connecticut, United States
- Norwalk Hospital
-
-
Florida
-
Miami, Florida, United States
- University of Miami School of Medicine
-
Panama City, Florida, United States
- Boehringer Ingelheim Investigational Site
-
-
Idaho
-
Coeur d'Arlene, Idaho, United States
- Boehringer Ingelheim Investigational Site
-
-
Illinois
-
River Forest, Illinois, United States
- Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Olathe, Kansas, United States
- Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, United States
- LSU MC-Sheveport
-
-
Maine
-
Auburn, Maine, United States
- Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States
- Johns Hopkins Asthma & Allergy
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Brigham & Women's Hospital
-
-
New Jersey
-
Berlin, New Jersey, United States
- Boehringer Ingelheim Investigational Site
-
Cherry Hill, New Jersey, United States
- Boehringer Ingelheim Investigational Site
-
-
New York
-
Manhasset, New York, United States
- North Shore University Hospital
-
New York, New York, United States
- NYU School of Medicine
-
-
North Carolina
-
Durham, North Carolina, United States
- Division of Pulmonary & Critical Care Medicine
-
Winston-Salem, North Carolina, United States
- Wake Forest University, Center for Human Genomics
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States
- Penn State University, Hershey Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States
- Boehringer Ingelheim Investigational Site
-
Spartanburg, South Carolina, United States
- Spartanburg Medical Research
-
-
Texas
-
Houston, Texas, United States
- Ben Taul General Hospital
-
Tyler, Texas, United States
- University of Texas Health Center at Tyler
-
-
Wisconsin
-
Madison, Wisconsin, United States
- University of Wisconsin Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient greater than or equal to 18 years of age,
- non-smokers,
- diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,
- stable use of Beta agonist
- daily use of inhaled steroids for one year
Exclusion Criteria:
- Patients with other significant diseases other than asthma, requiring oxygen,
- intubated within 5 years,
- asthma exacerbation within 6 weeks of trial,
- use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,
- participating in another interventional trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
FEV1 area under the curve (AUC) 0 to 6 hours Peak FEV1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
FEV1 at each timepoint Peak FVC FVC at each timepoint FVC AUC 0-6 Adverse events Vital signs
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
Other Study ID Numbers
Other Study ID Numbers
- 1012.50
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.